Panoptes Pharma is a clinical stage biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Panoptes’ development program focuses on a new treatment for orphan autoimmune uveitis, a disease which is one of the major causes of blindness. For this indication, PP-001 is developed as long-acting intravitreal injectable. Further indications in Panoptes’ focus are dry eye disease and adenoviral conjunctivitis to be treated with eye drops.
View Top Employees from Panoptes Pharma GmbH| Website | http://www.panoptes-pharma.com |
| Revenue | $8 million |
| Employees | 1 (0 on RocketReach) |
| Founded | 2013 |
| Phone | +43 664 8557369 |
| Technologies |
JavaScript,
HTML,
PHP
+26 more
(view full list)
|
| Industry | Biotechnology, Pharmaceuticals, Drug Discovery, Ophthalmology, Science and Engineering, Drug Development, Healthcare |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Panoptes Pharma GmbH employee's phone or email?
Panoptes Pharma GmbH Questions
The Panoptes Pharma GmbH annual revenue was $8 million in 2023.
Panoptes Pharma GmbH is based in Vienna, Vienna.
The NAICS codes for Panoptes Pharma GmbH are [325, 3254, 32541, 32].
The SIC codes for Panoptes Pharma GmbH are [28, 283].
Related Companies
